$IMNM News
Last published 2d ago
- 2d agoIMNMImmunome Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoIMNMImmunome Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness WireBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update. “We made significant progress across our oncology pipeline in recent months,” said Clay B. Siegall, Ph.D., Pre ...
- 5d agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options ...
- 1w agoIMNMImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness WireThe Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpoints If approved,
- 2w agoIMNMImmunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026Business WireRapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48 Four presentations build on the previously reported Phase 3 RINGSIDE results Immunome,
- 1mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026,
- 1mo agoIMNMImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsBusiness WireIM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal
- 2mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026,
- 2mo agoIMNMImmunome to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WireImmunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C.
- 3mo agoIMNMImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness WireVaregacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors Detailed Phase 3 RINGSIDE data presented in an oral session
- 3mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation
- 3mo agoIMNMImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid TumorsBusiness WireIM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.The Phase 1 trial is designed to evaluate the safety,
- 4mo agoIMNMImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness WirePDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved Immunome, Inc. (NASDAQ:IMNM), a biotechnology company
- 4mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation
- 5mo agoIMNMImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsBusiness WireIM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome's proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC pipeline momentum anticipated to
- 5mo agoIMNMImmunome, Inc. - 1764415 - IMMUNOME INCEarnings Call TranscriptsGreat. Good morning, everyone. Thank you for joining us. It's my pleasure to introduce Immunome. And with us, we have Max Rosette, CFO of the company. Max, to start here, thank you for joining us, Immunom is a targeted o
- 5mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of
- 5mo agoIMNMImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingBusiness WireVaregacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement in worst pain intensity
- 5mo agoIMNMImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman
- 6mo agoIMNMImmunome Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness WireNew Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed Phase 3 RINGSIDE data
- 6mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of
- 6mo agoIMNMImmunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid TumorsBusiness WireNew Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key
- 6mo agoIMNMImmunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual MeetingBusiness WireImmunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3,
- 7mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee
- 8mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee
- 8mo agoIMNMImmunome Reports Full Year 2025 Financial Results and Provides Business UpdateBusiness WireNew Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 IM-1021 Phase 1 ongoing with initial data expected in 2026 Three IND submissions for solid tumor-targeted ADC
- 8mo agoIMNMImmunome to Present at Upcoming Investor ConferencesBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following
- 9mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation
- 9mo agoAUTLIMNMMRNAONCY+1The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswireVANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and
- 9mo agoIMNMImmunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at Guggenheim's Emerging
- 11mo agoIMNMImmunome Announces Pricing of Public Offering of Common StockBusiness WireImmunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of
- 11mo agoCNTXIMNMONCYPRLD+1Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster
- 11mo agoIMNMImmunome Announces Proposed Public Offering of Common StockBusiness WireImmunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering,
- 11mo agoIMNMImmunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid TumorsBusiness WireRegistrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with
- 11mo agoIMNMImmunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid TumorsBusiness WireCompany to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced
- 11mo agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation
- 11mo agoIMNMImmunome to Present at Upcoming Investor ConferencesBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will participate in the
- 1y agoIMNMImmunome Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of
- 1y agoIMNMImmunome to Present at 2nd Annual Guggenheim Healthcare Innovation ConferenceBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 2nd Annual Guggenheim
- 1y agoIMNMImmunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC ResistanceBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Oct. 1, 2025, the Compensation Committee of
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee
- 1y agoIMNMImmunome to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th
- 1y agoIMNMImmunome Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided
- 1y agoIMNMINSMKURARPTXOMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit CommitteeGlobeNewswirePRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of
- 1y agoASPIIMNMASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer TreatmentGlobeNewswire- IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2025, the Compensation Committee of
- 1y agoIMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of